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ABSTRACT 
OBJECTIVE:  
The objective of this selective EBM review is to determine whether or not daily intake of 
glucosamine supplements prevents the need for knee replacements later in life for adults 
predisposed to osteoarthritis. 
STUDY DESIGN: 
Review of three English language primary randomized controlled trial studies published 
between 2001 and 2008 
DATA SOURCES:  
Three double blind randomized control trials comparing glucosamine supplements to 
placebo were found using PubMed. 
OUTCOMES MEASURED: 
Outcomes were measured using radiographic studies of the knees, joint space 
measurements, and symptoms were evaluated using Lequesne and WOMAC indexes.   
RESULTS: 
The Reginster (2001) and Pavelka (2002) studies demonstrated no change in joint space 
measurements in the experimental glucosamine group and a 20-25% decrease in 
symptoms such as pain and stiffness in the Pavelka study. In the Bruyere (2008) study, 19 
out of 131 (14.5%) of those in the placebo group underwent total joint replacement five 
years after the trial and 9 out of 144 (6.3%) of those in the experimental glucosamine 
group underwent total joint replacement  five years after the trial.   
CONCLUSIONS: 
The three randomized controlled trial in this review concluded that glucosamine 
supplements retard the progression of joint space narrowing and will delay the need for a 
total joint replacement up to five years after discontinuing glucosamine supplements.  
KEY WORDS: 
Glucosamine, Osteoarthritis, joint space narrowing, total joint replacements 
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Introduction 
 Knee Osteoarthritis (OA) is the most common form of osteoarthritis and fifth 
leading cause of disability in the United States
1
. The only cure for knee OA is total joint 
replacement (TJR). Knee osteoarthritis is conventionally managed symptomatically using 
anti-inflammatory medication such as naproxen and over-the-counter (OTC) pain 
medications. Unlike Rheumatoid arthritis, there is not a disease modifying medication, 
like the DMARD class of medication, for osteoarthritis. Thus, healthcare providers are 
treating the symptoms without slowing the progression of cartilage breakdown. As the 
patient’s function deteriorates further, symptomatic treatment becomes ineffective and 
TJR is warranted.  Glucosamine supplements have been advertised as OTC supplements 
for alleviating joint pain and promoting joint health. Research has shown that 
glucosamine supplements have the potential of slowing down the progression of joint 
space narrowing when compared to placebo while improving OA symptoms and 
restoring function.   
 The use of glucosamine supplements in the management of OA is relevant to 
patients and the physician assistant (PA) practice because managing OA can be a 
financial burden on the patient and the loss of function can be life changing. 
Approximately 27 million Americans suffer from OA
1
.  In the western world, 5-15% of 
people 35-74 years of age will have radiographic changes on knee studies such as joint 
space narrowing
2
.  Since OA is common, the cost of management and treatment is a 
burden on society.  In 2007, the cost for arthritis was $128 billion per year in medical 
care and indirect expenses such as lost wages
3
.  As of 2004, the total annual cost of OA 
per person was estimated to be $5700
3
.  As for the number of visits per year, in 1993, it 
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was estimated that an OA patient schedules 3.3 office visits per year
1
.  Current data is 
unavailable due to the type of management the patient is seeking (such as injections, 
post-op, etc).   
 Osteoarthritis is a degenerative progressive condition characterized by joint pain, 
joint stiffness after activities, as well as osteophyte formation seen on radiographic 
studies. It also includes the breakdown of cartilage in the joints which causes the 
symptoms mentioned above. The exact cause of osteoarthritis is unknown and therefore 
thought to be idiopathic. However, it is associated with obesity, repetitive motion, 
injuries, and aging.  
 As mentioned above, OA is treated symptomatically with analgesics such as 
Tylenol.  Synovial joint injections are also used lubricate the knee and prevent the “bone-
on-bone” rubbing due to cartilage lose.  Physical and occupational therapy as well as 
weight reduction are also implemented in the management of OA
3
.   
 Currently, TJR is the definitive cure for knee arthritis. Not all of those affected by 
OA are eligible for TJR. In general, the surgeon considers the patient’s health, severity of 
the symptoms, extend of the disability, as well as age. Surgeons are less likely to perform 
TJR on a younger person, less than 65 years old, due to the life-expectancy of the 
prosthetic components—a younger person will more likely have to undergo a revision 
surgery later on in life to replace worn out prosthetic components.  The revision surgery 
is more difficult than TJR and carries more risks and complications as well. Therefore, a 
supplement with disease retarding capability will benefit the patients and reduce the 
number of procedures they may undergo in their lifetime. Glucosamine sulfate has been 
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shown to slow down the progression of knee arthritis and preserving the joint space. 
Since the joint space is maintained, the patients’ symptoms lessen in severity or even 
cease. Thus restoring function and productivity as well as delaying the need for a surgical 
intervention such as a total joint replacement. This eliminates the financial burden of 
having multiple surgical interventions and improving the patients’ quality of life.  
Objective: 
 The objective of this selective EBM review is to determine whether or not daily 
intake of glucosamine supplements prevents the need for knee replacements later in life 
of adults predisposed to osteoarthritis. 
Methods: 
  Studies were selected based on population and type of intervention. The studies 
selected focused on adults over 18 years of age with OA symptoms.  The intervention 
was oral glucosamine supplements. The studies compared the treatment group which 
received 1500mg of oral glucosamine supplements daily and the control group which 
received a placebo daily.  The outcomes were measured using radiographic imaging to 
measure the joint space. The tibiofemoral joint space was measured and compared to the 
measurement taken prior to the start of the trial. Symptoms were assessed using algo-
functional indexes of Lequesne and WOMAC. All three studies were randomized placebo 
controlled trials.  
 A detailed search using PubMed and EBSCOhost was conducted using 
glucosamine supplements and knee osteoarthritis as keywords. All of the articles found 
and used in this review were published in peer-reviewed journals and written in English 
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between 2001 and 2008. The author of this review conducted the research and selected 
the studies based on the relevance and on the importance of outcomes to the patients 
(POEMS). The inclusion criteria were randomized controlled double blind studies 
performed after 1996 using glucosamine as an intervention. The exclusion criteria were 
patients over the age of 18, patients with hip arthritis, and using chondroitin as an 
intervention.  The statistics reported and used were 95% confidence intervals, numbers-
needed to harm (NNH), and p-values. 
Table 1: Demographics and characteristics of included studies 
Study Type # 
pt 
Age Inclusion 
criteria 
Exclusion 
criteria 
W/D Intervention 
Pavelka
1
 
(2002) 
Double 
blind 
RCT 
202 45-
70 
Primary knee 
OA 
-diagnoses 
based on 
clinical and 
radiological 
criteria of the 
American 
College 
of 
Rheumatology 
-minimum 
score of 4 on 
Lequesne 
index 
-Lequesne 
score of 12 
- history of 
articular and 
rheumatic 
diseases other 
than OA 
- history of 
traumas or 
lesions of the 
knee 
-severe 
articular 
inflammation 
- rapidly 
progressive 
osteoarthritis 
-overweight 
(BMI >27). 
- systemic or 
intra-articular 
corticosteroid 
use 3 months 
prior to trial. 
81 1500mg 
glucosamine 
sulfate PO 
QD x 3 years 
Reginster
4 
(2001) 
Double 
blind 
RCT 
212 >50 Primary knee 
OA and over 
age 50 
-history or 
active 
presence of 
73 1500mg 
glucosamine 
sulfate PO 
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other 
rheumatic 
diseases 
-severe 
articular 
inflammation 
-traumatic 
knee lesions 
-overweight 
(BMI >30) 
-intra-articular 
or systemic 
corticosteroids 
in the 3 
months prior 
to trial 
QD x 3 years 
Bruyere
5
 
(2008) 
Double 
blind 
RCT 
275 40-
70 
Participation 
in 3 year trial 
in the past 
Had TKR 
surgery after 
pervious trial 
0 Followed for 
incidence of 
TJR 
 
Outcomes measured: 
 The outcomes measured were patient oriented evidence that matters (POEMs). 
The objective data was measured using radiographic studies. The radiographic studies 
were conducted at the time of enrollment, after one year of treatment, and after 3 years of 
treatment. The medial joint space of the knee was then measured. To assess the 
symptoms, the Reginster et. al study used WOMAC while the Pavelka et. al used 
Lequesne and WOMAC.  The Western Ontario and McMaster Universities Arthritis 
Index (WOMAC) is used to assess the severity of arthritis related symptoms such as pain 
(score from 0-20), stiffness (score 0-8), and function limitations (score 0-68)
4
. The 
Lequesne Algo-functional index measures pain, distance walked, and activities of daily 
living
5
.  
Results: 
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 In Pavelka, et. al, there was progressive joint space loss in the placebo group 
while there was no progression in joint space narrowing in the glucosamine group. At the 
end of the 3 year trial, there was 0.36mm difference in joint space between the two 
groups with 95% confidence interval of 0.13-0.59mm and a p-value <0.001.
2 
Table 2: Intent-to-Treat Cumulative Joint Space Narrowing (in mm) at Each Year of 
Treatment  
Year Placebo Glucosamine Difference p-Value 
1 -0.04 -0.05 0.097 0.049 
2 -0.08 -0.03 0.11 0.030 
3 -0.19 -0.04 0.23 0.001 
 
As for the symptoms, the glucosamine group had a 20%-25% score reduction on the 
WOMAC and Lequesne indexes with p-value of 0.02 for WOMAC and <0.001 for 
Lequesne. In addition, the joint stiffness subscale of the WOMAC had a significant 
reduction in the glucosamine group with -0.31 95% confidence interval (CI) compared to 
the placebo group which had 0.11 95% CI. 
2
 The authors of the study included adverse 
events reported by the patients during the three year trial.  66% of the placebo group and 
64% of the glucosamine group reported at least one adverse event over the course of the 
three years
2
. The authors did not report significant differences between the groups and the 
adverse events reported. 
Table 3: Adverse Events reported by participants during the course of the trial
2
 
System Organ Class Placebo Glucosamine 
Gastrointestinal tract and liver  28 25 
Musculoskeletal  22 30 
Cardiovascular  20 23 
Skin and appendages  15 10 
Respiratory tract  7 17 
Urinary tract  11 12 
Metabolic and nutritional  6 7 
Other* 14 14 
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* Isolated adverse events : nervous, psychiatric, blood cell disorders, neoplasms, endocrine disorders, 
reproductive (male/female), vision disorders, hearing, and vestibular. 2 
 In Reginster et. al. study, the intention-to-treat analysis showed a lower mean 
joint space narrowing in the glucosamine group compared to the placebo group. The 
mean joint space narrowing for the glucosamine group was -0.06mm while the placebo 
group was -0.31mm with a 95% CI of 0.24 (0.01-0.08) and p-value of 0.043 
6
. As for the 
symptoms, the WOMAC index shows worsening of symptoms in the placebo group by 
the end of the three year trial when compared to the glucosamine group. The difference 
between the final group averages at the end of the three year period was significant 
(p=0.016)
6
. In addition, the study reports an improvement of function and pain on the 
WOMAC subscales in the glucosamine group. The authors of the study noted that there 
was improvement of symptoms in the glucosamine group even when the joint space 
narrowing was considered severe. With regards to adverse events, most of the 
participants reported at least one adverse event, 93% in the placebo group and 94% in the 
glucosamine group. The authors did not report any differences between the groups with 
regards to frequency of events or type of event
6
. The table below is a summary of the 
events reported by the participants. 
Table 5: Adverse events reported during Reginster et al trial
6 
Adverse Event Placebo Glucosamine 
Abdominal pain  18 13 
Dyspepsia  8 4 
Diarrhea  11 10 
Increased blood pressure  15 15 
Decreased blood pressure 8 2 
Cardiac failure  7 4 
Fatigue 7 10 
Headache  4 6 
Vertigo  3 7 
Neuritis  6 4 
Depressive mood  7 4 
Allergic episode  7 4 
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 In Bruyere et al study, 19 out of 131 (14.5%) placebo recipients underwent a total 
joint replacement surgery within the 5 years following the end of the trial. Only 9 out of 
144 (6.3%) glucosamine recipients underwent TJR after the trial. In other words, twice as 
many participants in the placebo group underwent TJR compared to the glucosamine 
group. The study reported a p-value of 0.024 and relative risk of undergoing TJR of 0.43 
(95% CI from 0.20 to 0.92) for the glucosamine group participants—a 57% decrease 
compared to the placebo group. The reported NNT to avoid TJR was 12 
7
. With regards 
to adverse events, the authors did not report adverse events during the course of the trial.  
Discussion: 
 The use of glucosamine sulfate supplements as a daily supplement for an 
extended period of time has proven effective in delaying the progression of Osteoarthritis 
and thus the need to undergo total joint replacement surgeries. Glucosamine sulfate 
supplements are readily available over-the-counter in pharmacies, supermarkets, and 
health stores such as GNC. After conducting an online price search, the prices of 
glucosamine sulfate supplements ranged from $9 to $35. It is considered a relatively safe 
supplement with minimal adverse reactions, such as constipation, diarrhea, nausea, 
vomiting, and pruritus
8
. There are no contraindications for glucosamine
8
.  Most of the 
studies performed up to this date investigated the effects of glucosamine on patients with 
OA. However, there are studies looking at the effects of the compound on weight loss, 
glaucoma, multiple sclerosis, and cancer
8
. Other uses for glucosamine have not been 
studied as extensively as the use for OA.  
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 Some drug interactions were reported for glucosamine sulfate. There is a major 
interaction warning for the use of glucosamine with Coumadin
9
. There has been several 
reports of glucosamine increasing the effect of Coumadin thus causing easy bruising and 
increasing the risk for serious bleeds.  There may be a moderate interaction between 
antimitotic chemotherapy and glucosamine. There is a chance that glucosamine may 
increase the rate of cell division which may decrease the effectiveness of cancer 
medications intended to reduce the rate of cell division in tumors
9
. In addition, 
glucosamine may increase blood sugar levels in diabetics and may decrease the 
effectiveness of diabetic medications
8,9
. Glucosamine is not contraindicated in diabetics 
but diabetic patients are advised to monitor their blood sugar levels more cautiously when 
taking glucosamine supplements.    
 The three studies were not limited with regard to sample size and duration of the 
trial. However, more studies are necessary to adequately conclude that glucosamine 
supplements may have disease-modifying effects on patients with Osteoarthritis. In 
addition, the studies should mention the source of glucosamine used in the trial. Since 
glucosamine is a supplement, it is not FDA monitored and the purity of the OTC 
supplement should be questioned. There have been reports in the media of OTC 
supplements with compounds not listed on the bottle which caused adverse events in the 
users.   
Conclusion: 
 All three studies have shown that glucosamine did retard the progression of 
osteoarthritis in adults with knee arthritis and did delay the need for total joint 
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replacement when compared to the placebo group. In addition, those who received 
glucosamine reported improvement of OA symptoms such as improved function and 
decrease in pain. Future studies are warranted to evaluate the effects of glucosamine 
sulfate on young athletes, such as runners and basketball players, who tend to develop 
OA symptoms at a young age. The study would include athletes between the ages of 18 
and 25 with mild knee pain or previous knee injuries which predispose them to OA. It 
would be interesting to see if glucosamine supplements will halt the progression of joint 
space narrowing and improve joint function in such active subjects.  
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